# Vaccine Therapy Plus Sargramostim and Interleukin-2 Compared With Nilutamide Alone in Treating Patients With Prostate Cancer

> **NCT00020254** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)**

## Conditions studied

- Prostate Cancer

## Interventions

- **BIOLOGICAL:** aldesleukin
- **BIOLOGICAL:** recombinant fowlpox-prostate specific antigen vaccine
- **BIOLOGICAL:** recombinant vaccinia prostate-specific antigen vaccine
- **BIOLOGICAL:** recombinant vaccinia-B7.1 vaccine
- **BIOLOGICAL:** sargramostim
- **DRUG:** nilutamide

## Key facts

- **NCT ID:** NCT00020254
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-06
- **Primary completion:** 2004-10
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2015-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00020254

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00020254, "Vaccine Therapy Plus Sargramostim and Interleukin-2 Compared With Nilutamide Alone in Treating Patients With Prostate Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00020254. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*